Showing 1 - 10 of 34
Operation Warp Speed (OWS) was a U.S. government-led program to accelerate the development, production, and administration of COVID-19 vaccines. The program cut the typical ten-year timeline needed to develop a new vaccine down to ten months and began vaccinating vulnerable populations within a...
Persistent link: https://www.econbiz.de/10015056157
Innovation policy involves trading off monopoly output and pricing in the short run in exchange for incentives for …
Persistent link: https://www.econbiz.de/10012481677
This paper introduces a newly digitized, open-access version of the Food and Drug Administration's "Orange Book"--a linkage between approved small-molecule drugs and the patents that protect them. The Orange Book also reports any applicable regulatory exclusivity that prevents competitive entry....
Persistent link: https://www.econbiz.de/10013462677
This study investigates how enhanced regulation can promote innovation, focusing on the impacts of a significant … recognized the improvement in drug innovation, as reflected in stock price adjustments post new drug registrations after the … latecomers could boost their innovation potential by adopting specific, effective regulatory practices from frontier countries …
Persistent link: https://www.econbiz.de/10014447297
We examine the role of spillover learning in shaping the value of exploratory versus incremental R&D. Using data from … firms learn about future projects. Firms appear to put more value on evaluation versus learning, and those patterns are in …
Persistent link: https://www.econbiz.de/10014287391
We utilize a novel identification strategy to analyze the impact of assets in place on firms' decisions for future projects. We exploit the context in the pharmaceutical industry, where the loss of market exclusivity for a branded drug can be used to separate the impact of cash flows generated...
Persistent link: https://www.econbiz.de/10012481442
Investment in intangible capital--in particular, research and development--increased dramatically since the 1990s. However, productivity growth remains sluggish in recent years. One potential reason is that a significant share of the increase in intangible investment is geared toward consumer...
Persistent link: https://www.econbiz.de/10012482573
This paper models how the evolving field of pharmacogenomics (PG), which is the science of using genomic markers to predict drug response, may impact drug development times, attrition rates, costs, and the future returns to research and development (R&D). While there still remains an abundance...
Persistent link: https://www.econbiz.de/10012466796
Previous empirical studies that have examined the links between pharmaceutical price controls, profits, cash flows, and investment in research and development (R&D) have been largely based on retrospective statistical analyses of firm- and/or industry-level data. These studies, which have...
Persistent link: https://www.econbiz.de/10012467571
pharmaceutical advertising, allows us to model individual prescription decisions. Second, we distinguish across-patient learning of a … drug?s general efficacy from the within-patient learning of the match between a drug and a patient. Our results suggest … January 2002, doctors held a strong prior belief about the efficacy of Celebrex, Vioxx, and Bextra. As a result, the learning …
Persistent link: https://www.econbiz.de/10012464395